Yaojin Peng (2016) Nature Biotechnology, http://www.ncbi.nlm.nih.gov/pubmed/27281418
While the focus of CRISPR patents has been on the US battle between the University of California-Berkley and the Broad Institute, other countries patent systems, such as China, have been largely ignored. Recently many more patent applications have been submitted to the Chinese State Intellectual Property Office. The number of pending applications and the use of non-viable human embryos in CRISPR experiments have raised questions as to how the Chinese patent system works. In this article Yaojin Peng describes in detail the kinds of inventions that are allowed to be patented in China and how ethics influences patent decisions. In particular Peng focuses on the kinds of CRISPR patents that could be awarded and those that would violate Chinese patent law.